论文部分内容阅读
目的 :探讨肿瘤异常蛋白(tumor abnormal protein,TAP)及血清肿瘤标记物包括胚胎型抗原标记物CEA、黏蛋白抗原类标记物CA15-3和CA125在局部晚期乳腺癌新辅助化疗的疗效评价上是否有意义。方法:对接受新辅助化疗(部分患者接受靶向治疗)的68例局部晚期乳腺癌患者进行回顾性分析。按照化疗效果将其分为病理完全缓解(p CR)、部分缓解(PR)、病灶稳定(SD)和疾病进展(PD),其中p CR+PR定义为反应组,SD+PD为无反应组。所有患者在化疗前及手术前均进行了TAP、CEA、CA125及CA15-3的检测,比较其在反应组和无反应组的数值差异及数值变化是否具有统计学意义。结果 :对化疗前后反应组和无反应组中各肿瘤标记物数值进行比较,除TAP在化疗后有统计学意义外(P<0.05),其余均无统计学意义(P>0.05);对化疗前后两组中各标记物升降变化情况进行比较,TAP及CA15-3的变化有统计学意义(P<0.05),而CEA及CA125无统计学意义(P>0.05)。结论 :TAP及CA15-3在评估乳腺癌新辅助化疗疗效方面可能存在一定意义。
Objective: To investigate whether tumor abnormal protein (TAP) and serum tumor markers including embryonic antigen marker CEA, mucin antigen markers CA15-3 and CA125 in the evaluation of the efficacy of neoadjuvant chemotherapy for locally advanced breast cancer Significant. Methods: A retrospective analysis was performed on 68 patients with locally advanced breast cancer receiving neoadjuvant chemotherapy (some of whom received targeted therapy). According to the chemotherapy effect, we divided them into pathologic complete response (PR), partial remission (PR), stable lesion (SD) and disease progression (PD) . All patients underwent TAP, CEA, CA125 and CA15-3 tests before and before chemotherapy. The differences in the values and the changes in the values between the response and non-response groups were statistically significant. Results: The values of tumor markers in response group and non-reaction group before and after chemotherapy were statistically different except TAP after chemotherapy (P <0.05) There was significant difference between the two groups (P <0.05), but there was no significant difference between CEA and CA125 (P> 0.05). Conclusion: TAP and CA15-3 may have some significance in assessing the efficacy of neoadjuvant chemotherapy for breast cancer.